Patents Examined by Blondel Hazel
  • Polypeptides having interferon activity
    Patent number: 4816566
    Abstract: A polypeptide having interferon activity which has an amino acid sequence corresponding to an amino acid sequence of an interferon selected from rIFN-.alpha., hybrid rIFN-.alpha., rIFN-.beta. and rIFN-.gamma. interferons in which at least one cysteine residue in the amino acid sequence has been replaced by an amino acid residue which is incapable of forming intermolecular disulfide bonds is provided. There are also provided a dsDNA sequence encoding the novel polypeptide; a replicable plasmidic expression vehicle containing the dsDNA encoding the novel polypeptides of the invention; a microorganism which has been transformed with the replicable plasmidic expression vehicle; and a method of preparing the dsDNA which encodes the novel polypeptides of the invention.
    Type: Grant
    Filed: February 10, 1986
    Date of Patent: March 28, 1989
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Thomas M. DeChiara, Stanley J. Tarnowski, Jr.
  • Multichain polypeptides or proteins and processes for their production
    Patent number: 4816397
    Abstract: Multichain polypeptides or proteins and processes for their production in cells of host organisms which have been transformed by recombinant DNA techniques. According to a first aspect of the present invention, there is provided a process for producing a heterologous multichain polypeptide or protein in a single host cell, which comprises transforming the host cell with DNA sequences coding for each of the polypeptide chains and expressing said polypeptide chains in said transformed host cell. According to another aspect of the present invention there is provided as a product of recombinant DNA technology an Ig heavy or light chain or fragment thereof having an intact variable domain. The invention also provides a process for increasing the level of protein expression in a transformed host cell and vectors and transformed host cells for use in the processes.
    Type: Grant
    Filed: November 14, 1984
    Date of Patent: March 28, 1989
    Assignee: Celltech, Limited
    Inventors: Michael A. Boss, John H. Kenten, John S. Emtage, Clive R. Wood
  • Interleukin 2 receptor and a method for production thereof
    Patent number: 4816565
    Abstract: Interleukin 2 receptor protein having the following properties:(a) molecular weight: 40 to 43 kd,(b) pI of 5.2 to 4.
    Type: Grant
    Filed: August 11, 1986
    Date of Patent: March 28, 1989
    Assignee: Tasuku Honjo
    Inventors: Tasuku Honjo, Akira Shimizu
  • Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
    Patent number: 4816253
    Abstract: A novel mutant strain of Listeria monocytogenes, termed by me "Listeria monocytogenes akka", has been discovered which functions as a killed strain not only as an antigen resulting in the production of relatively large titers of IgM antibodies in host animals but also as an immunopotentiating agent when conjugated to a sensitising antigen, for example, living tumor cells and herpes simplex virus. The high molecular weight IgM antibodies are readily separated from serum and recovered without loss of appreciable activity. The IgM antibodies can be divided into five subunits of IgG antibodies, of lesser molecular weight, having the same specificity as the IgM immunoglobulins. When the sensitizing antigens conjugated with the Listeria monocytogenes strain of this invention are tumor cells, the conjugate acts as an immunotherapeutic agent effective in cancer immunotherapy.
    Type: Grant
    Filed: December 10, 1985
    Date of Patent: March 28, 1989
    Inventor: Vilas V. Likhite
  • Stable formulation of biologically active proteins for parenteral injection
    Patent number: 4816440
    Abstract: A pharmaceutical composition containing IL-2 or IFN-.beta. dissolved in a suitable carrier medium at pH 7.0 to 8.0 stabilized with sodium laurate is suitable for parenteral injection into humans or animals. This formulation may be prepared by adding to either protein, after its recovery from a transformed organism, an effective amount of sodium laurate at a pH of 9 to 9.5 and then adjusting the pH of the formulation to between 7.0 and 8.0.
    Type: Grant
    Filed: September 26, 1985
    Date of Patent: March 28, 1989
    Assignee: Cetus Corporation
    Inventor: James W. Thomson
  • Process for the production of anti-human protein antibody
    Patent number: 4814169
    Abstract: The present invention relates to a process for the production of anti-human protein antibody, comprising induction of the antibody production in non-human warm-blooded animal cells capable of producing said antibody by injecting into a non-human warm-blooded animal a human protein-saccharide conjugate, obtained by covalent attachment of a human protein with a saccharide, and harvesting the resulting anti-human protein antibody. The antibody, prepared according to the invention, contains an extremely higher amount of immunoglobulin G than that obtained by conventional method while it contains slight or substantially no immunoglobulin E. Therefore, the antibody can be used advantageously for diagnostic, prophylactic or therapeutic administration in the prevention and treatment of human diseases.
    Type: Grant
    Filed: June 20, 1986
    Date of Patent: March 21, 1989
    Assignee: Kabushika Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Masakazu Mitsuhashi, Shunsaku Koyama
  • Method for preparing high conversion syrups and other sweeteners
    Patent number: 4814267
    Abstract: An improved method of preparing high maltose conversion syrups and other sweeteners from starch substrates comprises saccharifying the starch at higher temperatures than presently used with environmentally compatible thermostable .beta.-amylase and other thermostable enzymes.
    Type: Grant
    Filed: December 29, 1986
    Date of Patent: March 21, 1989
    Assignee: Michigan Biotechnology Institute
    Inventors: Joseph G. Zeikus, Badal C. Saha
  • Microbial production of mature human leukocyte interferon K and L
    Patent number: 4810645
    Abstract: This invention relates to the microbial production, via recombinant DNA technology, of new human leukocyte interferons, Le IF-K and Le IF-L for use in the treatment of viral and neoplastic diseases, and to the means and end products of such production.
    Type: Grant
    Filed: January 27, 1986
    Date of Patent: March 7, 1989
    Assignees: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: David V. Goeddel, Sidney Pestka
  • Constitutive production of human IFN-.beta.1 by mammalian cells transformed by the IFN-.beta.1 gene fused to an SV40 early promoter
    Patent number: 4808523
    Abstract: The invention concerns the production of the human fibroblast interferon, IFN-.beta.1 by cells of mammalian origin which are capable of constitutively expressing a DNA sequence encoding for IFN-.beta.1, producing the IFN and secreting it into the surrounding culture media.A specific embodiment of the invention comprises a methotrexate resistant chinese hamster ovary cell containing one or more pSVEIF molecules. The pSVEIF molecule contains a DNA sequence encoding for human INF-.beta.1 fused about 60 base pairs downstream from SV40 early start gene. The cell is capable of constitutively expressing the sequence encoding IFN-.beta.1, producing IFN-.beta.1 glycoprotein and secreting it into the surrounding medium.The invention also concerns methods of producing IFN-.beta. by culturing and growing the cells of the invention, and isolating and purifying the IFN-.beta.1 product.
    Type: Grant
    Filed: November 7, 1984
    Date of Patent: February 28, 1989
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michel Revel, Menachem Rubinstein
  • Interferon combinations
    Patent number: 4806347
    Abstract: There are disclosed compositions and methods for treating tumors and viruses in humans by administering a combination of gamma interferon and delta-4 alpha-2 (Bgl II-1)/(Bgl II) alpha-1 hybrid interferon, preferably by injection.
    Type: Grant
    Filed: December 11, 1985
    Date of Patent: February 21, 1989
    Assignee: Schering Corporation
    Inventor: Paul J. Leibowitz
  • Monoclonal antibody to a human thymocyte antigen
    Patent number: 4806629
    Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 70% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapuetic uses of the monoclonal antibody are also disclosed.
    Type: Grant
    Filed: March 23, 1987
    Date of Patent: February 21, 1989
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Patrick C. Kung, Gideon Goldstein
  • Detoxification of chlorinated aromatic compounds by organism NRRL B-18087
    Patent number: 4804629
    Abstract: Pseudomonas pseudoalcaligenes strain NRRL B-18087 was isolated as a pure culture from the Baton Rouge sewage treatment plant. The strain can utilize chlorinated aromatic compounds as the sole carbon source and will degrade both 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), as well as other xenobiotic compounds.
    Type: Grant
    Filed: August 4, 1986
    Date of Patent: February 14, 1989
    Assignee: Louisiana State University
    Inventor: Dipak Roy
  • Immunomodulation
    Patent number: 4803072
    Abstract: An immunomodulating pharmaceutical composition comprising an effective, leukocyte interferon production inducing amount of NS1 and a pharmaceutically acceptable carrier or diluent; and a method of modulating the immune response in a human or other animal in need thereof by inducing the production of leukocyte IFN which comprises administering an effective amount of NS1 to such human or animal.
    Type: Grant
    Filed: September 10, 1986
    Date of Patent: February 7, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Barbara J. Dalton, Robert C. Rees
  • Monoclonal antidigoxtin antibodies
    Patent number: 4803167
    Abstract: The present invention discloses a hybridoma culture and high affinity monoclonal antidigoxin antibodies produced by somatic cell fusion. The antibodies are useful for therapeutic as well as for diagnostic purposes. They are also useful in a model system for the study of structure-function relationships in antigen-antibody specific reactions.
    Type: Grant
    Filed: March 30, 1982
    Date of Patent: February 7, 1989
    Assignee: The General Hospital Corporation
    Inventors: Edgar Haber, Meredith Mudgett-Hunter, Michael Margolies
  • High titer pseudomonas immune serum globulin
    Patent number: 4801450
    Abstract: Normal plasma from donors who have not been vaccinated with a P seudomonas vaccine or had a Pseudomonas infection can be screened for higher than normal titers of naturally occurring antibody to four or, preferably, two of seven Fisher Immunotypes of Pseudomonas. Those plasmas with higher titers of such antibody can be pooled and fractionated to give hyperimmune serum globulin having high titers of antibody against all seven Fisher Immunotypes. The product may be treated to render it intravenously injectable and the so-prepared material is effective in treating patients with Pseudomonas infection. Also disclosed is a novel antibody preparation including minimum titers of the seven Fisher Immunotypes.
    Type: Grant
    Filed: May 5, 1986
    Date of Patent: January 31, 1989
    Assignee: Miles Laboratories, Inc.
    Inventors: Michael S. Collins, Robert E. Roby
  • Microbial production of mature human leukocyte interferon K and L
    Patent number: 4801685
    Abstract: This invention relates to the microbial production, via recombinant DNA technology, of new human leukocyte interferons, Le IF-K and Le IF-L for use in the treatment of viral and neoplastic diseases, and to the means and end products of such production.
    Type: Grant
    Filed: June 1, 1987
    Date of Patent: January 31, 1989
    Assignees: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: David V. Goeddel, Sidney Pestka
  • Chimeric peptides for neuropeptide delivery through the blood-brain barrier
    Patent number: 4801575
    Abstract: Chimeric peptides adapted for delivering neuropharmaceutical agents, such as neuropeptides into the brain by receptor-mediated transcytosis through the blood-brain barrier. The chimeric peptides include a peptide which by itself is capable of crossing the blood-brain barrier by transcytosis at a relatively high rate. The transportable peptide is conjugated to a hydrophilic neuropeptide which by itself is transportable only at a very low rate into the brain across the blood-brain barrier. The resulting chimeric peptide is transported into the brain at a much higher rate than the neuropeptide alone to thereby provide an effective means for introducing hydrophilic neuropeptides into the brain through the blood-brain barrier.
    Type: Grant
    Filed: July 30, 1986
    Date of Patent: January 31, 1989
    Assignee: The Regents of the University of California
    Inventor: William M. Pardridge
  • cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity
    Patent number: 4798789
    Abstract: Plasmid vectors are provided that carry complementary DNA (cDNA) clones cng for polypeptides exhibiting murine interleukin-2 activity. One of these polypeptides is 168 amino acids in length, including a potential leader sequence of about 19 amino acids. The cDNA is derived from messenger RNA isolated from a mouse T-cell line after activation with concanavalin A. The cDNA was cloned by incorporation into a plasmid vector, which is then transformed into E. coli. The plasmid vector also contained DNA segments from the SV40 virus, permitting expression of the cDNA after transfection into a mammalian host cell, such as monkey COS-7 cells.
    Type: Grant
    Filed: December 17, 1986
    Date of Patent: January 17, 1989
    Assignee: DNAX Research Institute of Molecular and Cellular Biology, Inc.
    Inventors: Frank D. Lee, Takashi Yokota, Ken-ichi Arai
  • Insecticidal hybrid bacteria from b.t. kurstaki and b.t. tenebrionis
    Patent number: 4797279
    Abstract: The invention provides hybrid microorganisms comprising the gene coding for b.t. kurstaki delta-endotoxin and the gene coding for b.t. tenebrionis delta-endotoxin, their preparation, insecticidal compositions comprising such microorganisms and their use.
    Type: Grant
    Filed: October 28, 1986
    Date of Patent: January 10, 1989
    Assignee: Sandoz Ltd.
    Inventors: Dimitri Karamata, Jean-Christophe Piot
  • Screening vaccines and immunization process
    Patent number: RE32833
    Abstract: Mammals are vaccinated against infectious organisms and polypeptides are screened for utility as vaccines by a complementing set of monoclonal antibodies, the first of which antibodies binds specifically to the site on the organism which itself binds specifically to a receptor on a host cell of the mammal, and the second of which binds specifically to the first. Vaccination is done with the second antibody alone, and screening is done by determining whether the polypeptide binds to the first antibody.
    Type: Grant
    Filed: December 23, 1986
    Date of Patent: January 17, 1989
    Assignee: President and Fellows of Harvard College
    Inventors: Mark I. Greene, Bernard N. Fields